Nina Möker joined Immatics in October 2023 and is leading the development of Immatics’ proprietary allogeneic, off-the-shelf adoptive cell therapy platform based on gamma delta T cells sourced from healthy donors.
Nina has more than 15 years of experience in the biomedical industry, starting with small molecules and moving on to therapeutic antibodies before dedicating herself to cell and gene therapy. She is driven by the real potential that immune cell therapy holds for solid tumor cancers. Her current work as Development Lead is focused on the advancement of Immatics’ next generation ACTallo® pipeline and portfolio, including progressing preclinical projects and their translation into early-phase clinical trials.
Nina earned her Ph.D. in Biochemistry at the University of Cologne, Germany and subsequently completed a postdoctoral fellowship with the Novartis Institutes for Biomedical Research in Cambridge, MA, USA.